Showing 1701-1710 of 2746 results for "".
- SecurityMetrics: HIPAA Report Reveals Healthcare's Shortcomingshttps://practicaldermatology.com/news/hipaa-report-reveals-healthcares-shortcomings/2458840/A significant security disparity exists among healthcare c-suite and IT departments, outlined by the SecurityMetrics HIPAA Security Rule Report. In a survey of c-level, risk officers, and IT managers, a 10-20% gap was revealed between what executives believe is happening in regards to patient dat
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officerhttps://practicaldermatology.com/news/industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/2460879/Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical c
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Hair Up Top: Restoration Names New CFOhttps://practicaldermatology.com/news/hair-up-top-restoration-names-new-cfo/2457955/Restoration Robotics, Inc. will have a new Chief Financial Officer next year. Industry veteran Mark L. Hair will fill the post effective January 5, 2018. Mr. Hair brings with him over 20 years of executive management, financial advisory, consulting, and public company exp
- Meta-Analysis IDs Promising Therapies for Hidradenitis Suppurativahttps://practicaldermatology.com/news/meta-analysis-ids-promising-therapies-for-hidradenitis-suppurativa/2475515/A new network meta-analysis comparing treatments for moderate to severe hidradenitis suppurativa (HS) shows several agents offering significantly improved efficacy over placebo. Researchers reviewed phase 2 and 3 randomized c
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c